Parwati Ida, Pitaloka Dian Ayu Eka, Chaidir Lidya
Department of Clinical Pathology, Faculty of Medicine, Universitas Padjadjaran, Sumedang 45363, Indonesia.
Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia.
Trop Med Infect Dis. 2022 Oct 22;7(11):326. doi: 10.3390/tropicalmed7110326.
Many blood-based gene expression biomarkers for monitoring tuberculosis (TB) treatment have been suggested so far, but promising biomarker results for drug-resistant TB treatment response have not been studied. This protocol presents a prospective observational study in Indonesia to profile the human blood transcriptome for predicting the response to drug-resistant TB treatment, focusing on pulmonary TB, and to adapt the specific RNA signature to the qRT-PCR platform. Longitudinal blood samples will be collected from 44 subjects with rifampicin resistant TB, confirmed by Xpert MTB/RIF, and 52 healthy controls. RNA-Seq will be performed to identify changes in the transcriptome following TB treatment. A discriminative RNA signature will be chosen and translated into a score for use in a quantitative PCR-based assay. This study will provide crucial information to guide the discovery and design of a clinically implementable tool to monitor the response of TB treatment.
到目前为止,已经提出了许多用于监测结核病(TB)治疗的血液基因表达生物标志物,但尚未对耐多药结核病治疗反应的有前景的生物标志物结果进行研究。本方案介绍了在印度尼西亚进行的一项前瞻性观察性研究,以分析人类血液转录组,预测耐多药结核病治疗反应,重点是肺结核,并使特定的RNA特征适用于qRT-PCR平台。将从44名经Xpert MTB/RIF确诊的耐利福平结核病患者和52名健康对照中采集纵向血样。将进行RNA测序以确定结核病治疗后转录组的变化。将选择一个有鉴别力的RNA特征并转化为一个分数,用于基于定量PCR的检测。本研究将提供关键信息,以指导发现和设计一种临床可实施的工具来监测结核病治疗反应。